Published in BJU Int on September 30, 2010
Urinary nerve growth factor as an oncologic biomarker for prostate cancer aggressiveness. Urol Oncol (2014) 1.42
Role of mast cells in male chronic pelvic pain. J Urol (2012) 1.07
Etiology of chronic prostatitis/chronic pelvic pain syndrome: psychoimmunoneurendocrine dysfunction (PINE syndrome) or just a really bad infection? World J Urol (2013) 0.93
NGF - the TrkA to successful pain treatment. J Pain Res (2012) 0.92
Nociceptive and inflammatory mediator upregulation in a mouse model of chronic prostatitis. Pain (2015) 0.81
Mast Cell-Mediated Mechanisms of Nociception. Int J Mol Sci (2015) 0.80
Immune mediators of chronic pelvic pain syndrome. Nat Rev Urol (2014) 0.78
Inhibition of endogenous NGF degradation induces mechanical allodynia and thermal hyperalgesia in rats. Mol Pain (2013) 0.77
Anorectal and Pelvic Pain. Mayo Clin Proc (2016) 0.75
Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats. Eur Urol (2008) 2.24
Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int (2004) 2.11
Urologic complications of diabetes. Diabetes Care (2005) 2.03
Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol (2009) 2.03
Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol (2008) 1.96
Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology (2005) 1.81
Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology (2005) 1.77
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother (2010) 1.70
Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase. Cancer Res (2005) 1.65
Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol (2006) 1.62
Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res (2007) 1.61
Expression of IL-8 during reperfusion of renal allografts is dependent on ischemic time. Transplantation (2006) 1.60
Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. BJU Int (2005) 1.56
How sacral nerve stimulation neuromodulation works. Urol Clin North Am (2005) 1.55
Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.54
Abrupt enlargement of adrenal incidentaloma: a case of isolated adrenal metastasis. Endocr J (2005) 1.51
Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey. BJU Int (2011) 1.50
Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats. J Neurosci (2006) 1.48
Complete mutation analysis panel of the 39 human HOX genes. Teratology (2002) 1.47
Current and future pharmacological treatment for overactive bladder. J Urol (2002) 1.47
Transabdominal ultrasonography of detrusor wall thickness in women with overactive bladder. BJU Int (2009) 1.46
Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium. Neurourol Urodyn (2013) 1.46
The future of urodynamics: non-invasive ultrasound videourodynamics. Int J Urol (2010) 1.46
Emerging role of botulinum toxin in the treatment of neurogenic and non-neurogenic voiding dysfunction. Curr Urol Rep (2002) 1.44
Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc (2003) 1.43
High-energy transurethral microwave thermotherapy in patients with benign prostatic hyperplasia: comparative study between 30-and 60-minute single treatments. Acta Med Okayama (2004) 1.42
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol (2008) 1.41
Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J Urol (2002) 1.41
Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int (2006) 1.40
Inhibitory role of the spinal galanin system in the control of micturition. Urology (2013) 1.39
Cool (TRPM8) and hot (TRPV1) receptors in the bladder and male genital tract. J Urol (2004) 1.36
Accuracy of two noninvasive methods of diagnosing bladder outlet obstruction using ultrasonography: intravesical prostatic protrusion and velocity-flow video urodynamics. Urology (2005) 1.35
Description of a 23.9-kilobase chromosomal deletion containing a region encoding fsr genes which mainly determines the gelatinase-negative phenotype of clinical isolates of Enterococcus faecalis in urine. Appl Environ Microbiol (2002) 1.34
T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun (2007) 1.34
Decreased expression of REIC/Dkk-3 in human renal clear cell carcinoma. J Urol (2004) 1.33
Urethral closure mechanisms under sneeze-induced stress condition in rats: a new animal model for evaluation of stress urinary incontinence. Am J Physiol Regul Integr Comp Physiol (2003) 1.32
The role of bladder-to-urethral reflexes in urinary continence mechanisms in rats. Am J Physiol Renal Physiol (2004) 1.29
Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int (2009) 1.28
Rehabilitation and medical management of the adult with spina bifida. Am J Phys Med Rehabil (2008) 1.26
Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol (2007) 1.25
Inhibitory and excitatory perigenital-to-bladder spinal reflexes in the cat. Am J Physiol Renal Physiol (2007) 1.25
Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis. Cancer Res (2008) 1.24
Suppression of detrusor-sphincter dyssynergia by immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord injured rats. J Urol (2004) 1.24
The application of botulinum toxin in the prostate. J Urol (2006) 1.22
Bladder Cancer Working Group report. Jpn J Clin Oncol (2010) 1.21
Improved sphincter contractility after allogenic muscle-derived progenitor cell injection into the denervated rat urethra. Urology (2003) 1.21
Fiber kinematics of small intestinal submucosa under biaxial and uniaxial stretch. J Biomech Eng (2006) 1.20
Effect of duloxetine, a norepinephrine and serotonin reuptake inhibitor, on sneeze-induced urethral continence reflex in rats. Am J Physiol Renal Physiol (2008) 1.20
Identification of c-kit-positive cells in the mouse ureter: the interstitial cells of Cajal of the urinary tract. Am J Physiol Renal Physiol (2003) 1.19
Japanese guidelines for prevention of perioperative infections in urological field. Int J Urol (2007) 1.19
Role of noradrenergic pathways in sneeze-induced urethral continence reflex in rats. Am J Physiol Renal Physiol (2006) 1.18
Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int (2009) 1.17
Overexpression of REIC/Dkk-3 in normal fibroblasts suppresses tumor growth via induction of interleukin-7. J Biol Chem (2009) 1.17
The other bladder syndrome: underactive bladder. Rev Urol (2013) 1.17
Delayed treatment of bladder outlet obstruction after sling surgery: association with irreversible bladder dysfunction. J Urol (2004) 1.17
Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasis. Am J Pathol (2003) 1.16
Comparison of leak point pressure methods in an animal model of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2005) 1.16
Comparative study of oncologic outcome of laparoscopic nephroureterectomy and standard nephroureterectomy for upper urinary tract transitional cell carcinoma. Urology (2007) 1.14
Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol (2004) 1.12
Testosterone replacement elevates the serum uric acid levels in patients with female to male gender identity disorder. Endocr J (2013) 1.12
Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology (2004) 1.12
Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther (2007) 1.12
Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol (2003) 1.10
Prevalence of overactive bladder and associated risk factors in 1359 patients with type 2 diabetes. Urology (2011) 1.10
Short-term outcomes of Greenlight HPS laser photoselective vaporization prostatectomy (PVP) for benign prostatic hyperplasia (BPH). J Endourol (2008) 1.10
Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J Urol (2006) 1.10
Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol (2009) 1.09
Reactive oxygen species mediate detrusor overactivity via sensitization of afferent pathway in the bladder of anaesthetized rats. BJU Int (2007) 1.09
Immunological aspects of REIC/Dkk-3 in monocyte differentiation and tumor regression. Int J Oncol (2009) 1.09
Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum Gene Ther (2003) 1.08
Green onions: potential mechanism for hepatitis A contamination. J Food Prot (2006) 1.07
Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamide-induced cystitis. Urology (2008) 1.07
Muscle derived stem cell therapy for stress urinary incontinence. World J Urol (2008) 1.06
Opr86 is essential for viability and is a potential candidate for a protective antigen against biofilm formation by Pseudomonas aeruginosa. J Bacteriol (2008) 1.06
Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol (2004) 1.06
Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J Urol (2009) 1.05
Diabetic cystopathy correlates with a long-term decrease in nerve growth factor levels in the bladder and lumbosacral dorsal root Ganglia. J Urol (2002) 1.05
Genetic profiles of fluoroquinolone-resistant Escherichia coli isolates obtained from patients with cystitis: phylogeny, virulence factors, PAIusp subtypes, and mutation patterns. J Clin Microbiol (2009) 1.05
A tissue-engineered suburethral sling in an animal model of stress urinary incontinence. BJU Int (2005) 1.05
REIC/Dkk-3 as a potential gene therapeutic agent against human testicular cancer. Int J Mol Med (2007) 1.04
Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination. Int J Cancer (2011) 1.04